353 related articles for article (PubMed ID: 30859124)
1. Long-term clinical value and outcome of riociguat in chronic thromboembolic pulmonary hypertension.
van Thor MCJ; Ten Klooster L; Snijder RJ; Post MC; Mager JJ
Int J Cardiol Heart Vasc; 2019 Mar; 22():163-168. PubMed ID: 30859124
[TBL] [Abstract][Full Text] [Related]
2. Predictors of long-term outcomes in patients treated with riociguat for chronic thromboembolic pulmonary hypertension: data from the CHEST-2 open-label, randomised, long-term extension trial.
Simonneau G; D'Armini AM; Ghofrani HA; Grimminger F; Jansa P; Kim NH; Mayer E; Pulido T; Wang C; Colorado P; Fritsch A; Meier C; Nikkho S; Hoeper MM
Lancet Respir Med; 2016 May; 4(5):372-80. PubMed ID: 27067478
[TBL] [Abstract][Full Text] [Related]
3. Does combination therapy work in chronic thromboembolic pulmonary hypertension?
van Thor MCJ; Snijder RJ; Kelder JC; Mager JJ; Post MC
Int J Cardiol Heart Vasc; 2020 Aug; 29():100544. PubMed ID: 32518816
[TBL] [Abstract][Full Text] [Related]
4. Long-term real world clinical outcomes of macitentan therapy in chronic thromboembolic pulmonary hypertension.
van Thor MCJ; Ten Klooster L; Snijder RJ; Mager JJ; Post MC
Respir Med; 2020 Jun; 167():105966. PubMed ID: 32421542
[TBL] [Abstract][Full Text] [Related]
5. Use of responder threshold criteria to evaluate the response to treatment in the phase III CHEST-1 study.
D'Armini AM; Ghofrani HA; Kim NH; Mayer E; Morsolini M; Pulido-Zamudio T; Simonneau G; Wilkins MR; Curram J; Davie N; Hoeper MM
J Heart Lung Transplant; 2015 Mar; 34(3):348-55. PubMed ID: 25813765
[TBL] [Abstract][Full Text] [Related]
6. Soluble Guanylate Cyclase Stimulators and Activators: Novel Therapies for Pulmonary Vascular Disease or a Different Method of Increasing cGMP?
Koress C; Swan K; Kadowitz P
Curr Hypertens Rep; 2016 Apr; 18(5):42. PubMed ID: 27118316
[TBL] [Abstract][Full Text] [Related]
7. Beneficial effects of riociguat on hemodynamic responses to exercise in CTEPH patients after balloon pulmonary angioplasty - A randomized controlled study.
Aoki T; Sugimura K; Terui Y; Tatebe S; Fukui S; Miura M; Yamamoto S; Yaoita N; Suzuki H; Sato H; Kozu K; Konno R; Miyata S; Nochioka K; Satoh K; Shimokawa H
Int J Cardiol Heart Vasc; 2020 Aug; 29():100579. PubMed ID: 32685661
[TBL] [Abstract][Full Text] [Related]
8. Riociguat therapy for pulmonary hypertension: a systematic review and meta-analysis.
Wang L; Zhu L; Wu Y; Li Q; Liu H
Ann Palliat Med; 2021 Oct; 10(10):11117-11128. PubMed ID: 34763472
[TBL] [Abstract][Full Text] [Related]
9. Riociguat for patients with chronic thromboembolic pulmonary hypertension: Usefulness of transitioning from phosphodiesterase type 5 inhibitor.
Yamamoto K; Tanabe N; Suda R; Sasaki A; Matsumura A; Ema R; Kasai H; Kato F; Sekine A; Nishimura R; Jujo T; Sugiura T; Shigeta A; Sakao S; Tatsumi K
Respir Investig; 2017 Jul; 55(4):270-275. PubMed ID: 28705306
[TBL] [Abstract][Full Text] [Related]
10. Haemodynamic effects of riociguat in CTEPH and PAH: a 10-year observational study.
Yang S; Yang Y; Zhang Y; Kuang T; Gong J; Li J; Li Y; Wang J; Guo X; Miao R
ERJ Open Res; 2021 Jul; 7(3):. PubMed ID: 34513985
[TBL] [Abstract][Full Text] [Related]
11. Balloon pulmonary angioplasty combined with riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (PRACTICE study): study protocol for a randomized controlled trial.
Zhao QH; Gong SG; He J; Yuan P; Wu WH; Luo CJ; Jiang R; Zhang R; Qiu HL; Li HT; Li Y; Liu JM; Wang L
Trials; 2021 Dec; 22(1):957. PubMed ID: 34961562
[TBL] [Abstract][Full Text] [Related]
12. Riociguat for the treatment of pulmonary hypertension: Chinese subgroup analyses and comparison.
Wang C; Jing ZC; Huang YG; Zhou DX; Liu ZH; Meier C; Nikkho S; Curram J; Zhang P; He JG
Heart Asia; 2016; 8(1):74-82. PubMed ID: 27326239
[TBL] [Abstract][Full Text] [Related]
13. Balloon pulmonary angioplasty versus riociguat in inoperable chronic thromboembolic pulmonary hypertension (MR BPA): an open-label, randomised controlled trial.
Kawakami T; Matsubara H; Shinke T; Abe K; Kohsaka S; Hosokawa K; Taniguchi Y; Shimokawahara H; Yamada Y; Kataoka M; Ogawa A; Murata M; Jinzaki M; Hirata K; Tsutsui H; Sato Y; Fukuda K
Lancet Respir Med; 2022 Oct; 10(10):949-960. PubMed ID: 35926544
[TBL] [Abstract][Full Text] [Related]
14. Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial.
Ghofrani HA; Grimminger F; Grünig E; Huang Y; Jansa P; Jing ZC; Kilpatrick D; Langleben D; Rosenkranz S; Menezes F; Fritsch A; Nikkho S; Humbert M
Lancet Respir Med; 2016 May; 4(5):361-71. PubMed ID: 27067479
[TBL] [Abstract][Full Text] [Related]
15. Riociguat for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Results from a phase II long-term extension study.
Halank M; Hoeper MM; Ghofrani HA; Meyer FJ; Stähler G; Behr J; Ewert R; Fletcher M; Colorado P; Nikkho S; Grimminger F
Respir Med; 2017 Jul; 128():50-56. PubMed ID: 28610669
[TBL] [Abstract][Full Text] [Related]
16. Change of right heart size and function by long-term therapy with riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
Marra AM; Egenlauf B; Ehlken N; Fischer C; Eichstaedt C; Nagel C; Bossone E; Cittadini A; Halank M; Gall H; Olsson KM; Lange TJ; Grünig E
Int J Cardiol; 2015 Sep; 195():19-26. PubMed ID: 26011408
[TBL] [Abstract][Full Text] [Related]
17. Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension: Initial Single-Center Experience.
Anand V; Frantz RP; DuBrock H; Kane GC; Krowka M; Yanagisawa R; Sandhu GS
Mayo Clin Proc Innov Qual Outcomes; 2019 Sep; 3(3):311-318. PubMed ID: 31485569
[TBL] [Abstract][Full Text] [Related]
18. Riociguat for pulmonary arterial hypertension associated with congenital heart disease.
Rosenkranz S; Ghofrani HA; Beghetti M; Ivy D; Frey R; Fritsch A; Weimann G; Saleh S; Apitz C
Heart; 2015 Nov; 101(22):1792-9. PubMed ID: 26135803
[TBL] [Abstract][Full Text] [Related]
19. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension.
Ghofrani HA; D'Armini AM; Grimminger F; Hoeper MM; Jansa P; Kim NH; Mayer E; Simonneau G; Wilkins MR; Fritsch A; Neuser D; Weimann G; Wang C;
N Engl J Med; 2013 Jul; 369(4):319-29. PubMed ID: 23883377
[TBL] [Abstract][Full Text] [Related]
20. Bosentan or Macitentan Therapy in Chronic Thromboembolic Pulmonary Hypertension?
van Thor MCJ; Ten Klooster L; Snijder RJ; Kelder JC; Mager JJ; Post MC
Lung; 2019 Dec; 197(6):753-760. PubMed ID: 31583452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
